Close Menu

NEW YORK (GenomeWeb) — IntegraGen announced today that it is collaborating with investigators from the FIRE-3 clinical trial to study the use of a microRNA biomarker to predict clinical outcomes in metastatic colorectal cancer patients treated with anti-EGFR therapies.

The FIRE-3 study is a Phase III trial comparing FOLFIRI — Camptosar (irinotecan) with fluorouracil and folinic acid — in combination with either Erbitux (cetuximab) or Avastin (bevacizumab) as a first-line therapy in patients with KRAS exon 2 wild-type stage IV colorectal cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.